News
Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point
Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...
Clinical Trials Arena on MSN4d
Viatris’ blepharitis ointment fails Phase III trialViatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the ...
Reflecting ongoing concerns around drug quality in India's pharmaceutical supply chain, the Central Drugs Standard Control Organisation (CDSCO) has flagged 130 drug samples as Not ...
Spain's SpliceBio has raised $135m in financing that will help it move a gene-editing therapy for Stargardt disease through clinical testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback